Skip to main content
. 2020 May 19;13:4365–4372. doi: 10.2147/OTT.S247796

Figure 1.

Figure 1

Biomarker screening and qRT-PCR validation. (A) circRAPGEF5 and hsa_circ_0058124 were differentially expressed in the training cohort of 52 patients with PTC and 50 HCs; (B) expression profile of circRAPGEF5 and hsa_circ_0058124 in 33 PTC patients at pre- and post-treatment; (C) expression levels of circRAPGEF5 and hsa_circ_0058124 were significantly up-regulated in patients with PTC compared with thyroid nodule and HCs. *P<0.05.

Abbreviations: PTC, papillary thyroid cancer; HC, healthy control.